amsacrine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 9 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-two patients (mean age 41 years) in blast crisis or accelerated phase (AP) of chronic myelogenous leukemia (CML) were treated with cytosine arabinoside (Ara-C) 500 mg/m2 [intermediate dose] or 1000 mg/m2 [high dose] twice a day for 6 days and amsacrine (AMSA) 120 mg/m2 for 3 days." | 8.78 | Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine. ( Bauduer, F; Blanc, MC; Cadiou, M; Delmas-Marsalet, B; Delmer, A; Marie, JP; Rio, B; Zittoun, R, 1993) |
| "Twenty-two patients (mean age 41 years) in blast crisis or accelerated phase (AP) of chronic myelogenous leukemia (CML) were treated with cytosine arabinoside (Ara-C) 500 mg/m2 [intermediate dose] or 1000 mg/m2 [high dose] twice a day for 6 days and amsacrine (AMSA) 120 mg/m2 for 3 days." | 4.78 | Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine. ( Bauduer, F; Blanc, MC; Cadiou, M; Delmas-Marsalet, B; Delmer, A; Marie, JP; Rio, B; Zittoun, R, 1993) |
| "Amsacrine treatment triggered SIDT2-mediated miR-25 downregulation, leading to increased NOX4-mediated ROS production." | 1.91 | Amsacrine downregulates BCL2L1 expression and triggers apoptosis in human chronic myeloid leukemia cells through the SIDT2/NOX4/ERK/HuR pathway. ( Chang, LS; Chen, YJ; Chiou, JT; Lee, YC; Wang, LJ, 2023) |
| " The pharmacokinetic data served as a guideline for in vitro toxicity tests on clonogenic bone marrow cells." | 1.29 | Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ( Brons, P; de Witte, T; Knops, G; Linssen, P; Wessels, H, 1993) |
| "Four had an antecedent chronic phase of chronic myelogenous leukemia and 15 presented with ALL." | 1.28 | Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) is resistant to effective therapy for Ph1-negative ALL. ( Ahmed, T; Arlin, ZA; Feldman, EJ; Liebowitz, D; Shapiro, LR; Wilmot, PL, 1989) |
| "Thus, the CR rate for relapsed ANLL patients who received the higher doses of both agents was 40% (13 of 33)." | 1.28 | Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine. ( Dahl, GV; Grier, HE; Kalwinsky, DK; Mason, C; Mirro, J; Murphy, SB; Santana, VM, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, YC | 1 |
| Chiou, JT | 1 |
| Wang, LJ | 1 |
| Chen, YJ | 1 |
| Chang, LS | 1 |
| López-Lázaro, M | 1 |
| Pastor, N | 1 |
| Azrak, SS | 1 |
| Ayuso, MJ | 1 |
| Cortés, F | 1 |
| Austin, CA | 1 |
| Bauduer, F | 1 |
| Delmer, A | 1 |
| Blanc, MC | 1 |
| Delmas-Marsalet, B | 1 |
| Cadiou, M | 1 |
| Rio, B | 1 |
| Marie, JP | 1 |
| Zittoun, R | 1 |
| Linssen, P | 1 |
| Brons, P | 1 |
| Knops, G | 1 |
| Wessels, H | 1 |
| de Witte, T | 1 |
| Meloni, G | 1 |
| Capria, S | 1 |
| Vignetti, M | 1 |
| Mandelli, F | 1 |
| Modena, V | 1 |
| Constantinou, A | 1 |
| Grdina, D | 1 |
| Kiguchi, K | 1 |
| Huberman, E | 1 |
| Arlin, ZA | 1 |
| Feldman, EJ | 1 |
| Ahmed, T | 1 |
| Liebowitz, D | 1 |
| Shapiro, LR | 1 |
| Wilmot, PL | 1 |
| Mirro, J | 1 |
| Kalwinsky, DK | 1 |
| Grier, HE | 1 |
| Santana, VM | 1 |
| Mason, C | 1 |
| Murphy, SB | 1 |
| Dahl, GV | 1 |
| Cervantes, F | 1 |
| López Guillermo, A | 1 |
| Rozman, M | 1 |
| Rozman, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia[NCT01690065] | Phase 2 | 46 participants (Anticipated) | Interventional | 2012-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amsacrine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; C | 1993 |
8 other studies available for amsacrine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Amsacrine downregulates BCL2L1 expression and triggers apoptosis in human chronic myeloid leukemia cells through the SIDT2/NOX4/ERK/HuR pathway.
Topics: Amsacrine; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Humans; K562 Cells; Leukemia, My | 2023 |
Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells.
Topics: Amsacrine; Antineoplastic Agents; Digitoxin; Dose-Response Relationship, Drug; Drug Screening Assays | 2006 |
Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L).
Topics: Acute Disease; Adult; Amsacrine; Blast Crisis; Bone Marrow; Bone Marrow Cells; Cell Division; Cell S | 1993 |
Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Blast Crisis; | 1997 |
The effect of topoisomerase inhibitors on the expression of differentiation markers and cell cycle progression in human K-562 leukemia cells.
Topics: Amsacrine; Aphidicolin; Cell Cycle; Cell Differentiation; Cycloheximide; Deoxyadenosines; Dose-Respo | 1992 |
Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) is resistant to effective therapy for Ph1-negative ALL.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evalu | 1989 |
Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; C | 1989 |
[Treatment with m-AMSA in the blast crisis of chronic myeloid leukemia].
Topics: Amsacrine; Blast Crisis; Drug Evaluation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; | 1988 |